Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of an intramuscular inactivated split-virion A/H5N1 influenza vaccine in adults and elderly
2006-000477-29Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of A/H5N1 inactivated split-virion influenza vaccine in Influenza A H5N1 infection (H5N1) and Influenza A infection (2 arms), sponsored by Sanofi. Primary endpoints: Injection-site safety profile, Systemic safety profile and 1 more. Started Mar 2006; status: completed.
02
Drugs
A/H5N1 inactivated split-virion influenza vaccine
03
Conditions
Influenza A H5N1 infection (H5N1)Influenza A infection
Beyond the preview
Go deeper on 2006-000477-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000477-29.